305 related articles for article (PubMed ID: 27697758)
21. Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda.
Mwesigwa J; Parikh S; McGee B; German P; Drysdale T; Kalyango JN; Clark TD; Dorsey G; Lindegardh N; Annerberg A; Rosenthal PJ; Kamya MR; Aweeka F
Antimicrob Agents Chemother; 2010 Jan; 54(1):52-9. PubMed ID: 19841149
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of two novel tablet formulations of artemether-lumefantrine (Coartem) for bioequivalence in a randomized, open-label, two-period study.
Lefèvre G; Bhad P; Jain JP; Kalluri S; Cheng Y; Dave H; Stein DS
Malar J; 2013 Sep; 12():312. PubMed ID: 24010572
[TBL] [Abstract][Full Text] [Related]
23. Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults.
Byakika-Kibwika P; Lamorde M; Mayito J; Nabukeera L; Namakula R; Mayanja-Kizza H; Katabira E; Ntale M; Pakker N; Ryan M; Hanpithakpong W; Tarning J; Lindegardh N; de Vries PJ; Khoo S; Back D; Merry C
J Antimicrob Chemother; 2012 Sep; 67(9):2213-21. PubMed ID: 22687893
[TBL] [Abstract][Full Text] [Related]
24. Population pharmacokinetics of artemether, lumefantrine, and their respective metabolites in Papua New Guinean children with uncomplicated malaria.
Salman S; Page-Sharp M; Griffin S; Kose K; Siba PM; Ilett KF; Mueller I; Davis TM
Antimicrob Agents Chemother; 2011 Nov; 55(11):5306-13. PubMed ID: 21876056
[TBL] [Abstract][Full Text] [Related]
25. Single low-dose tafenoquine combined with dihydroartemisinin-piperaquine to reduce Plasmodium falciparum transmission in Ouelessebougou, Mali: a phase 2, single-blind, randomised clinical trial.
Stone W; Mahamar A; Smit MJ; Sanogo K; Sinaba Y; Niambele SM; Sacko A; Keita S; Dicko OM; Diallo M; Maguiraga SO; Samake S; Attaher O; Lanke K; Ter Heine R; Bradley J; McCall MBB; Issiaka D; Traore SF; Bousema T; Drakeley C; Dicko A
Lancet Microbe; 2022 May; 3(5):e336-e347. PubMed ID: 35544095
[TBL] [Abstract][Full Text] [Related]
26. Safety and tolerability of artemether-lumefantrine versus dihydroartemisinin-piperaquine for malaria in young HIV-infected and uninfected children.
Katrak S; Gasasira A; Arinaitwe E; Kakuru A; Wanzira H; Bigira V; Sandison TG; Homsy J; Tappero JW; Kamya MR; Dorsey G
Malar J; 2009 Nov; 8():272. PubMed ID: 19948038
[TBL] [Abstract][Full Text] [Related]
27. Concomitant efavirenz reduces pharmacokinetic exposure to the antimalarial drug artemether-lumefantrine in healthy volunteers.
Huang L; Parikh S; Rosenthal PJ; Lizak P; Marzan F; Dorsey G; Havlir D; Aweeka FT
J Acquir Immune Defic Syndr; 2012 Nov; 61(3):310-6. PubMed ID: 22918158
[TBL] [Abstract][Full Text] [Related]
28. Sequential Open-Label Study of the Safety, Tolerability, and Pharmacokinetic Interactions between Dihydroartemisinin-Piperaquine and Mefloquine in Healthy Thai Adults.
Hanboonkunupakarn B; van der Pluijm RW; Hoglund R; Pukrittayakamee S; Winterberg M; Mukaka M; Waithira N; Chotivanich K; Singhasivanon P; White NJ; Dondorp AM; Tarning J; Jittamala P
Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31182525
[TBL] [Abstract][Full Text] [Related]
29. Four Artemisinin-Based Treatments in African Pregnant Women with Malaria.
; Pekyi D; Ampromfi AA; Tinto H; Traoré-Coulibaly M; Tahita MC; Valéa I; Mwapasa V; Kalilani-Phiri L; Kalanda G; Madanitsa M; Ravinetto R; Mutabingwa T; Gbekor P; Tagbor H; Antwi G; Menten J; De Crop M; Claeys Y; Schurmans C; Van Overmeir C; Thriemer K; Van Geertruyden JP; D'Alessandro U; Nambozi M; Mulenga M; Hachizovu S; Kabuya JB; Mulenga J
N Engl J Med; 2016 Mar; 374(10):913-27. PubMed ID: 26962727
[TBL] [Abstract][Full Text] [Related]
30. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for falciparum malaria: a longitudinal, randomized trial in young Ugandan children.
Arinaitwe E; Sandison TG; Wanzira H; Kakuru A; Homsy J; Kalamya J; Kamya MR; Vora N; Greenhouse B; Rosenthal PJ; Tappero J; Dorsey G
Clin Infect Dis; 2009 Dec; 49(11):1629-37. PubMed ID: 19877969
[TBL] [Abstract][Full Text] [Related]
31. Artenimol + piperaquine. Very slow piperaquine elimination: cardiovascular risks and interactions.
Prescrire Int; 2014 Jan; 23(145):5-8. PubMed ID: 24516901
[TBL] [Abstract][Full Text] [Related]
32. CYP2B6*6 Genotype Specific Differences in Artemether-Lumefantrine Disposition in Healthy Volunteers.
Abdullahi ST; Soyinka JO; Olagunju A; Bolarinwa RA; Olarewaju OJ; Bakare-Odunola MT; Winterberg M; Tarning J; Owen A; Khoo S
J Clin Pharmacol; 2020 Mar; 60(3):351-360. PubMed ID: 31549442
[TBL] [Abstract][Full Text] [Related]
33. Clinical efficacy of chloroquine versus artemether-lumefantrine for Plasmodium vivax treatment in Thailand.
Krudsood S; Tangpukdee N; Muangnoicharoen S; Thanachartwet V; Luplertlop N; Srivilairit S; Wilairatana P; Kano S; Ringwald P; Looareesuwan S
Korean J Parasitol; 2007 Jun; 45(2):111-4. PubMed ID: 17570973
[TBL] [Abstract][Full Text] [Related]
34. A randomized trial of dihydroartemisinin-piperaquine versus artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Mali.
Dama S; Niangaly H; Djimde M; Sagara I; Guindo CO; Zeguime A; Dara A; Djimde AA; Doumbo OK
Malar J; 2018 Oct; 17(1):347. PubMed ID: 30290808
[TBL] [Abstract][Full Text] [Related]
35. The interaction between artemether-lumefantrine and lopinavir/ritonavir-based antiretroviral therapy in HIV-1 infected patients.
Kredo T; Mauff K; Workman L; Van der Walt JS; Wiesner L; Smith PJ; Maartens G; Cohen K; Barnes KI
BMC Infect Dis; 2016 Jan; 16():30. PubMed ID: 26818566
[TBL] [Abstract][Full Text] [Related]
36. The efficacy of dihydroartemisinin-piperaquine and artemether-lumefantrine with and without primaquine on Plasmodium vivax recurrence: A systematic review and individual patient data meta-analysis.
Commons RJ; Simpson JA; Thriemer K; Abreha T; Adam I; Anstey NM; Assefa A; Awab GR; Baird JK; Barber BE; Chu CS; Dahal P; Daher A; Davis TME; Dondorp AM; Grigg MJ; Humphreys GS; Hwang J; Karunajeewa H; Laman M; Lidia K; Moore BR; Mueller I; Nosten F; Pasaribu AP; Pereira DB; Phyo AP; Poespoprodjo JR; Sibley CH; Stepniewska K; Sutanto I; Thwaites G; Hien TT; White NJ; William T; Woodrow CJ; Guerin PJ; Price RN
PLoS Med; 2019 Oct; 16(10):e1002928. PubMed ID: 31584960
[TBL] [Abstract][Full Text] [Related]
37. The pharmacokinetic properties of artemether and lumefantrine in Malaysian patients with Plasmodium knowlesi malaria.
Sugiarto SR; Singh B; Page-Sharp M; Davis WA; Salman S; Hii KC; Davis TME
Br J Clin Pharmacol; 2022 Feb; 88(2):691-701. PubMed ID: 34296469
[TBL] [Abstract][Full Text] [Related]
38. Understanding the pharmacokinetics of Coartem.
Djimdé A; Lefèvre G
Malar J; 2009 Oct; 8 Suppl 1(Suppl 1):S4. PubMed ID: 19818171
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetic interactions and safety evaluations of coadministered tafenoquine and chloroquine in healthy subjects.
Miller AK; Harrell E; Ye L; Baptiste-Brown S; Kleim JP; Ohrt C; Duparc S; Möhrle JJ; Webster A; Stinnett S; Hughes A; Griffith S; Beelen AP
Br J Clin Pharmacol; 2013 Dec; 76(6):858-67. PubMed ID: 23701202
[TBL] [Abstract][Full Text] [Related]
40. Tafenoquine exposure assessment, safety, and relapse prevention efficacy in children with Plasmodium vivax malaria: open-label, single-arm, non-comparative, multicentre, pharmacokinetic bridging, phase 2 trial.
Vélez ID; Hien TT; Green JA; Martin A; Sharma H; Rousell VM; Breton JJ; Ernest TB; Rolfe K; Taylor M; Mohamed K; Jones SW; Chau NH; Hoa NT; Duparc S; Tan LK; Goyal N
Lancet Child Adolesc Health; 2022 Feb; 6(2):86-95. PubMed ID: 34871570
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
